Skip to main content
. 2000 Mar 21;97(7):3406–3411. doi: 10.1073/pnas.060026497

Figure 3.

Figure 3

Failure for long-term survival not resulting from immunological rejection. (a) 2C CD8+ T cells from [B10 (H-2bThy-1bCD8b) × B10.TL (H-2bThy-1aCD8a)]F1 and from B10 genetic backgrounds were activated in separate cultures by B10.A B cell blasts with or without IL-4 addition, respectively. Each of three unirradiated B10.TL recipients was transferred with a mixture containing equal numbers (4 × 106 each) of the two differentially primed donor CD8+ populations. Staining PBL with F-anti-Thy-1.2 (30H12) + Cy5-anti-Thy-1.1 (LS693) allowed unambiguous detection of the relative percentage of the two types of donor cells (total donor cells as 100%), with Thy-1.1+Thy-1.2+ and Thy1.1−Thy-1.2+ phenotypes representing donor cells that were primed originally with or without IL-4, respectively. Because of the Thy-1.2− nature of host B10.TL T cells, they were clearly distinguishable from Thy-1.2+ donor CD8+ T cells. (b) 2C CD8+ T cells from B10 and (B10 × B10.TL)F1 genetic backgrounds were activated in separate cultures by B10.A peritoneal macrophages, with or without IL-4 addition, respectively. Each of four unirradiated B10.TL recipients was transferred with a mixture containing equal numbers (4 × 106 each) of the two differentially primed donor CD8+ populations. The relative percentage of IL-4-treated and untreated donor 2C CD8+ T cells was determined identically as in a, except that Thy1.1−Thy-1.2+ and Thy-1.1+Thy-1.2+ phenotypes represented donor cells that originally were primed with or without IL-4, respectively. (c) 2C CD8+ T cells from [B10 × B10.TL] F1 and from B10 genetic backgrounds were activated by B10 macrophages + 0.5 μg/ml SL8 peptide in separate cultures supplemented with IL-4 and IL-2 addition, respectively. Each of three unirradiated B10.TL recipients was transferred with a mixture containing equal numbers (3 × 106 each) of the two differentially primed donor CD8+ populations. The relative percentage of IL-4- and IL-2-treated donor 2C CD8+ T cells was determined identically as in a. Donor/total CD8+ ratios also were determined by staining with F-anti-Thy-1.2 + Cy5-anti-CD8 and consistent results with those presented in Figs. 1 and 2 were obtained (data not shown).